Reading: Management of severe retinopathy of prematurity in Jaffna

Download

A- A+
Alt. Display

Original Articles

Management of severe retinopathy of prematurity in Jaffna

Authors:

H. Abeysekera ,

Teaching Hospital Jaffna, LK
X close

S. T. S. Chandrakumar,

Teaching Hospital Jaffna, LK
X close

M. Malaravan,

Teaching Hospital Jaffna, LK
X close

L. Gurusinghe,

Teaching Hospital Jaffna, LK
X close

S. Jeyabalan,

Teaching Hospital Jaffna, LK
X close

Rajima Srinani,

Teaching Hospital Jaffna, LK
X close

K. Vicknan,

Teaching Hospital Jaffna, LK
X close

A. Joseph,

Teaching Hospital Jaffna, LK
X close

B. Gajalaksan

Teaching Hospital Jaffna, LK
X close

Abstract

Introduction and objectives: Treatment of Retinopathy of Prematurity (ROP) is revolutionized by the use of Anti-Vascular Endothelial Growth Factor agents over the last decade. This study describes the results of the treatment in the newest paediatric ophthalmology unit in Sri Lanka- Teaching hospital, Jaffna. Methods: Retrospective analysis of the ROP screening and treatment data at the paediatric ophthalmology unit at teaching hospital was carried out. All the screening and treatment sessions were carried out under topical anaesthesia. Out of the 118 babies who underwent screening examinations, 12 babies had severe ROP requiring treatment with intravitreal injection of Bevacizumab. In conclusion intravitreal injection of Bevacizumab is very successful in managing severe Zone 1 and Zone 2 ROP although prolong follow up is mandatory to detect recurrences of ROP.
How to Cite: Abeysekera H, Chandrakumar STS, Malaravan M, Gurusinghe L, Jeyabalan S, Srinani R, et al.. Management of severe retinopathy of prematurity in Jaffna. Jaffna Medical Journal. 2018;30(2):10–5. DOI: http://doi.org/10.4038/jmj.v30i2.19
Published on 28 Dec 2018.
Peer Reviewed

Downloads

  • Untitled (EN)

    comments powered by Disqus